Company
Technology
Team
Board of Directors
Management
Extended Management
Project Management
Partners & Advisors
Preclinical Research
Clinical Research
Strategic Investment
Investors
News
Company News
Scientific Publications
Contact
Company News
Finanz und Wirtschaft: RocketVax could become the new Moderna
16 November 2023
READ MORE
Rocketvax AG selected to participate in SIX Swiss Exchange Sparks IPO Academy
14 November 2023
READ MORE
Impfen wir bei Covid-19 bald über die Nase?
7 August 2023
READ MORE
Nasal vaccine against coronavirus further improved
13 June 2023
READ MORE
New vaccine concept against SARS-CoV-2 successfully tested
5 June 2023
READ MORE
Swiss Rockets AG Welcomes Three New Key Members To The Team
18 April 2023
READ MORE
RocketVax Nasal Vaccine to Prevent COVID-19 Passes First Tests
4 April 2023
READ MORE
CNN Health Reports About RocketVax Covid-19 Nasal Vaccine
3 April 2023
READ MORE
RocketVax has successfully completed another round of financing; The development of the second-generation COVID-19 vaccine moves forward
6 February 2023
READ MORE
Volker Thiel: "Wir planen noch besseren Corona-Impfschutz"
15 November 2022
READ MORE
RocketVax AG Announces New Milestones in the Development of Second-Generation COVID-19 Vaccines
23 September 2022
READ MORE
Dr. Vladimir Cmiljanovic is a recipient of the 2023 Nikola Tesla Spirit Award
31 January 2023
READ MORE
Burkhard Frey joins Rocketvax AG as Chief Commercial Officer
22 August 2022
READ MORE
SRF: Research on nasal corona vaccines raises hopes
22 August 2022
READ MORE
Dr. Milan Crnogorac joins RocketVax AG as Chief Technology Officer
9 August 2022
READ MORE
LOAD MORE NEWS